Dataset Information

An immunological and biochemical comparison of 67 kDa calcimedin and 67 kDa calelectrin.

ABSTRACT: The 67 kDa calcimedin is a Ca2+-binding protein isolated from several muscle tissues. A recent report [Morse & Moore (1988) Biochem. J. 251, 171-174] indicated that the 67 kDa calcimedin is distinct from 67 kDa calelectrin, which is purified from various non-muscle cells. In the present study we have purified the 67 kDa protein from bovine aorta (i.e. 67 kDa calcimedin) and liver (i.e. 67 kDa calelectrin) and compared them by immunological and biochemical criteria. The aorta calcimedin is identical with the liver calelectrin by the following criteria. (1) The calcimedin co-electrophoresed with the calelectrin on SDS/5-15%-(w/v)-linear-gradient polyacrylamide gels. (2) The two proteins selectively cross-reacted with a chicken gizzard calcimedin antibody. (3) An antibody raised against the bovine aorta calcimedin also recognized the bovine liver calelectrin. (4) One-dimensional peptide maps of the two proteins revealed no significant difference. (5) The calcimedin appeared to have an amino acid composition essentially the same as that of the liver calelectrin. (6) The amino acid sequences of the calcimedin fragments were identical with those of the calelectrin fragments.

SUBMITTER: Kobayashi R

PROVIDER: S-EPMC1133373 | biostudies-other | 1989 Sep

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Hence, new anti-liver cancer treatment strategies need to be urgently developed. Coptisine is a natural alkaloid extracted from rhizoma coptidis which exhibits anticancer activity in various preclinical models, including liver cancer. However, the molecular mechanisms underlying the anti-liver cancer effects of coptisine remains unclear. We used flow cytometry to assess the binding of coptisine to 67LR expressed on the surface of SMMC7721, HepG2, LO2 and H9 cells. Then SMMC7721, HepG2 and BEL7402 cells, belonging to the HCC cell lines, were treated with coptisine. The cell viability was detected using a cell counting kit-8 assay. Apoptosis was evaluated using flow cytometry and transferase-mediated dUTP nick-end labeling (TUNEL) assay. Apoptotic-related proteins and tumor death receptor 67-kDa laminin receptor (67LR) were detected using Western blot analysis. The cyclic guanosine 3',5'-monophosphate (cGMP) concentration was determined using enzyme-linked immunosorbent assay. sh67LR lentivirus, anti67LR antibody, and cGMP inhibitor NS2028 were used to determine how a 67LR/cGMP signaling pathway regulated coptisine-induced apoptosis. Tumor growth inhibited by coptisine was confirmed in a SMMC7721 cell xenograft mouse model. Coptisine selectively exhibited cell viability in human hepatoma cells but not in normal human hepatocyte cell line LO2 cells. Coptisine promoted SMMC7721 and HepG2 cell apoptosis by increasing 67LR activity. Both 67LR antibody and sh67LR treatment blocked coptisine-induced apoptosis and inhibition of cell viability. Coptisine upregulated the expression of cGMP. Moreover, cGMP inhibitor NS2028 significantly decreased coptisine-induced apoptosis and inhibition of cell viability. In vivo experiments confirmed that coptisine could significantly suppress the tumor growth and induce apoptosis in SMMC7721 xenografts through a 67LR/cGMP pathway. Coptisine-mediated 67LR activation may be a new therapeutic strategy for treating hepatic malignancy.

Dataset Information

An immunological and biochemical comparison of 67 kDa calcimedin and 67 kDa calelectrin.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets